Infertility is the inability of a person
to reproduce naturally. Female infertility is the inability of a woman
to become pregnant and carry pregnancy to full term. It is the most
common issue faced by couples trying to get conceived. The most commonly
diagnosed causes of female infertility are issues with ovulation;
hormonal imbalance; anatomical disorders of the reproductive system such
as damage caused to the fallopian tubes, the uterus, or the cervix;
overuse of alcohol or drugs; thyroid gland-associated issues; excessive
weight; and stress. Growing prevalence of polycystic ovarian syndrome
(PCOS) and other hormonal disorders, changing lifestyle, obesity, and
increasing awareness about advanced fertility techniques are some of
the factors expected to boost the global fertility diagnosis &
treatment market during the forecast period. However, high cost of
treatments, possibility of failure, and shortage of skilled medical
professionals in developing countries are expected to restrain the
global female infertility diagnosis & treatment market between 2017
and 2025.
Report Overview @ https://www.transparencymarketresearch.com/female-infertility-diagnosis-treatment-market.html
The global female infertility diagnosis
& treatment market can be segmented based on diagnosis type,
treatment type, end-user, and region. In terms of diagnosis type, the
market has been segmented into ovulation testing, blood & urine
testing to confirm presence of infection or imbalance in thyroid hormone
level, hysterosalpingography, ovarian reserve testing, imaging tests,
laparoscopy, genetic testing, and other hormone testing. In terms of
treatment type, the global female infertility diagnosis & treatment
market can be categorized into fertility restoration therapy and
reproductive assistance therapy. The fertility restoration therapy
segment can be sub-segmented based on drug type and surgery type. In
terms of drug type, the segment can be divided into clomiphene citrate,
gonadotropins, metformin, letrozole, and bromocriptine. Based on surgery
type, the fertility restoration therapy segment can be classified into
laparoscopic or hysteroscopic surgery and tubal surgery. The
reproductive assistance therapy segment can be further classified into
intrauterine insemination (IUI) therapy, intracytoplasmic sperm
injection (ICSI), gamete intrafallopian tube transfer, zygote
intrafallopian transfer (ZIFT), gamete intrafallopian tube transfer
(GIFT), and assisted reproductive technology (ART) or in-vitro
fertilization (IVF). Based on end-user, the global female infertility
diagnosis & treatment market can be divided into hospitals,
specialty clinics, and pathological & diagnostic centers. The
hospitals segment is expected to dominate the global market during the
forecast period.
Geographically, the global female
infertility diagnosis & treatment market can be segmented into North
America, Europe, Asia Pacific, Latin America, and Middle East &
Africa. North America is expected dominate the global market between
2017 and 2025, owing to increasing prevalence of hormonal disorders
caused by changing lifestyle, excessive alcohol consumption, lack of
exercise, and stress. According to a study by the University of Maryland
Medical Center (UMMC), in the U.S., about 10% of women aged between 15
and 44 are having difficulties in getting pregnant or carrying the
pregnancy to full term. Europe is the second-largest market for female
infertility diagnosis & treatment, owing to growing research and
development of novel fertility technologies and high awareness among
couples about finding solutions for their infertility issues. According
to the IVI, the largest assisted reproduction group in the world, in the
Europe, the number of couples and individuals approaching medical
practitioners for seeking advice to choose a suitable solution for
infertility is increasing by around 9% every year. Asia Pacific is
considered an emerging market for female infertility diagnosis &
treatment, owing to increasing population, presence of developing
economies, growing awareness about methods such as IVF and IUI, and
increasing per capita health care spending in the region.
Key players operating in the global
female infertility diagnosis & treatment market are Pfizer Inc.
Sanofi, Janssen Global Services, LLC, Novartis AG, Par Pharmaceutical,
Cook, Bayer AG, Bristol-Myers Squibb Company, Church & Dwight Co.,
Inc., CooperSurgical Inc., and EMD Serono, Inc.
No comments:
Post a Comment